Palisade Bio FY2030 EPS Reduced by Brookline Capital Markets

Palisade Bio, Inc. (NASDAQ:PALI) – Analysts at Brookline Capital Markets dropped their FY2030 EPS estimates for Palisade Bio in a research report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of $0.39 per share for the year, down from their previous forecast of $0.41. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.23) per share.

PALI has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Finally, Oppenheimer began coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Palisade Bio currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Palisade Bio Stock Down 5.1%

Shares of NASDAQ:PALI opened at $2.04 on Monday. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.86. The company has a 50-day moving average price of $1.97 and a 200 day moving average price of $1.92. The company has a market cap of $355.51 million, a P/E ratio of -4.25 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.50 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. XTX Topco Ltd raised its stake in shares of Palisade Bio by 53.8% during the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after buying an additional 7,584 shares during the last quarter. Cetera Investment Advisers acquired a new stake in Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio during the 4th quarter valued at about $26,000. Virtu Financial LLC purchased a new position in Palisade Bio during the 4th quarter valued at about $28,000. Finally, Atom Investors LP acquired a new position in Palisade Bio during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Insider Buying and Selling

In related news, insider Mitchell Lawrence Jones sold 51,880 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the completion of the transaction, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. The trade was a 35.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the transaction, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at approximately $450,338.85. This represents a 40.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have bought a total of 125,000 shares of company stock worth $250,100 in the last quarter. Company insiders own 0.07% of the company’s stock.

More Palisade Bio News

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Brokerage coverage remains broadly bullish: ten analysts have a consensus “Buy” rating, including seven Buy and two Strong Buy recommendations, versus one Sell rating. The reported consensus price target is $9.00, substantially above the stock’s recent trading level near $2.04. Brokerages Set Palisade Bio Price Target at $9
• Neutral Sentiment: The $9 target and Buy consensus reflect significant expected upside, but Palisade Bio remains unprofitable, with the company’s latest quarterly loss meeting expectations at $0.05 per share and revenue of approximately $0.50 million.
• Negative Sentiment: Brookline Capital Markets lowered its EPS forecast for the third and fourth quarters of 2026 to a loss of $0.06 per share from $0.05. Its full-year 2026 estimate was cut to a loss of $0.21 from $0.20, while the current consensus full-year estimate is a loss of $0.22.
• Negative Sentiment: The analyst also reduced longer-term loss estimates: FY2027 to $0.23 per share from $0.21, FY2028 to $0.27 from $0.25, and FY2029 to $0.38 from $0.35. These revisions suggest expectations for profitability have weakened and could weigh on valuation.
• Negative Sentiment: An additional report noted a reduction to Brookline’s FY2030 EPS estimate, extending the pattern of softer long-term earnings expectations. FY2030 EPS Estimate for Palisade Bio Decreased by Analyst

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.